ABT 072
Alternative Names: ABT-072Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 23 Aug 2012 Pharmacokinetics data from a preclinical trial in Hepatitis C presented at the 244th American Chemical Society National Meeting (244th-ACS-2012)
- 20 Apr 2012 Efficacy and adverse event data from a phase II trial in Hepatitis C virus infections presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL-2012)